Consolidation Immunotherapy After Platinum-Based Chemoradiotherapy in Patients With Unresectable Stage III Non-Small Cell Lung Cancer-Cross-Sectional Study of Eligibility and Administration Rates.

Front Oncol · 2020 · PMC7736629 · PMID 33335856

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

an increasing trendno p-value reported

In addition, 85% of these potentially eligible patients actually received CIT about 1 year after drug approval at a large European tertiary cancer center and the rate of CIT administration showed an increasing trend during that time period.

also in 63,971 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.